REMSleep Holdings Inc. Announces the DeltaWave and its Patent Application
27 July 2017 - 1:00AM
InvestorsHub NewsWire
July 24, 2017 12:21 ET
REMSleep Holdings Inc. Announces the DeltaWave and its Patent
Application -- A New Revolutionary CPAP Nasal Interface Device
Designed to Improve Treatment for Sleep Apnea Patients
DES MOINES, IA -- Jul 24, 2017 -- InvestorsHub
newsWire -- REMSleep Holdings, Inc. (OTC PINK: RMSL) (OTC
PINK: RMSLD) www.remsleeptech.com is pleased to
announce that it has filed a non-provisional patent with the US
Patent and Trademark Office (Patent number 15/595,990 filed on
March 16, 2017). The patent is titled "New Generation Sleep Apnea
Device" and will ultimately be marketed under the product name
"DeltaWave."
The patent pending DeltaWave is designed to allow patients to
breathe normally while on CPAP Therapy, a breakthrough that should
increase patient compliance dramatically. The DeltaWave is less
claustrophobic than traditionally used products, very lightweight,
minimizes or eliminates drying of the sinuses and requires less
driving pressure due to its unique generous airflow dynamics.
REMSleep Holdings is confident that DeltaWave's unique design will
benefit a wide range of patients offering a more compliant
interface by providing improved air flow dynamics and more ease of
breathing, resulting in deep restful sleep.
Sleep Apnea is a condition that causes a person to have periodic
episodes of interrupted breathing during sleep. Obstructive Sleep
Apnea (OSA) inhibits restorative sleep, carrying significant
implications such as cognitive impairment and even sudden cardiac
death. Treatment of this affliction to date has created a $4.9
Billion market with industry estimates anticipating a $6.7 Billion
market by year 2021. Treating this Global Epidemic is currently
addressed by patients using Continuous Positive Airway Pressure
(CPAP) machines and Interfaces (masks). Unfortunately, current
models continue to have issues that cause patients to give up on
treatment. Patient non-compliance is becoming a mounting concern
for the medical community.
It is estimated that approximately 50% of Sleep Apnea sufferers
who own a CPAP system are unable to continue treatment because of
non-compliance. Tom Wood, CEO, comments, "Our goal is to reach a
significant number of these patients with our new DeltaWave
Interface and provide a more compliant and comfortable treatment
for these, and new patients diagnosed with Sleep Apnea. Years of
research and development have led us to the DeltaWave, a design
that addresses the stubborn issues that continue to affect a
patient's ability to comply with treatment. The new DeltaWave is
truly different and unique because it addresses patient air intake
deprivation and does not interrupt a patient's normal respiratory
rate."
About REMSleep Holdings, Inc.
REMSleep Holdings, Inc. was founded to design and manufacture
devices and products for the treatment of sleep apnea and other
respiratory conditions. With over 50 years of collective experience
in CPAP therapy, the REMSleep team has extensive knowledge and
understanding of CPAP and the challenges of patient compliance.
REMSleep Holdings, Inc. has a new patent pending, innovative sleep
apnea product that will meet multiple market needs and be able to
reach and address a large percentage of the patient population who
continue to struggle with CPAP compliance.
Forward-looking statements
Some statements in this release may contain forward-looking
information. All statements, other than of historical fact, that
address activities, events or developments that the Company
believes, expects or anticipates will or may occur in the future
(including, without limitation, statements regarding potential
acquisitions and financings) are forward-looking statements.
Forward-looking statements are generally identifiable by use of the
words "may", "will", "should", "continue", "expect", "anticipate",
"estimate", "believe", "intend", "plan" or "project" or the
negative of these words or other variations on these words or
comparable terminology. Forward-looking statements are subject to a
number of risks and uncertainties, many of which are beyond the
Company's ability to control or predict, that may cause the actual
results of the Company to differ materially from those discussed in
the forward-looking statements. Factors that could cause actual
results or events to differ materially from current expectations
include, among other things, without limitation, the inability of
the Company to obtain sufficient financing to execute the Company's
business plan; competition; regulation and anticipated and
unanticipated costs and delays, and other risks disclosed in the
Company's public disclosure record on file with the relevant
securities regulatory authorities. Although the Company has
attempted to identify important factors that could cause actual
results or events to differ materially from those described in
forward-looking statements, there may be other factors that cause
results or events not to be as anticipated, estimated or intended.
Readers should not place undue reliance on forward-looking
statements. No information in this news release should be construed
to be an indication of the Company's future revenues, results of
operations or its stock price. The forward-looking statements
included in this news release are made as of the date of this news
release and the Company does not undertake an obligation to
publicly update such forward-looking statements to reflect new
information, subsequent events or otherwise unless required by
applicable securities legislation.
CONTACT INFORMATION
REMSleep Holdings, Inc.
Tom Wood
CEO
Russel Bird
President
515-724-5995
RemSleep (QB) (USOTC:RMSL)
Historical Stock Chart
From Apr 2024 to May 2024
RemSleep (QB) (USOTC:RMSL)
Historical Stock Chart
From May 2023 to May 2024